Revenio Group Oyj (0KFH) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon from snowy Finland and welcome to Revenio Q4 and full year 2025 earnings call. My name is Jouni Toijala. I'm the group CEO for Revenio. And then with me, as always, we have Robin Pulkkinen here as a CFO. Plan for today is to go through the business highlights for Q4 2025 and then couple of highlights also from the whole 2025. And then we are going to go through recap regarding to the three-year strategy period, focusing on the strategy execution during 2025, and then Robin is going to take over and go through the financials for the Q4 2025, and then the whole year 2025, and then we'll finish up with the guidance for 26, and of course the Q&A at the end. Q4, net sales grew to 31.2 million, so reported growth 2.2%, currency-adjusted growth 8.6%. And if you think and go back for the Q4 from the region perspective, so Q4, US sales grew strongly and we received the all-time sales record in the USA during the December. Also strong growth in Europe, Middle East, Africa region. And if you look for the APAC, so a bit more similar trend during the Q4. For APAC as we had for Q3, so the sales was down year on year, but on the positive note, Now the tide bit turned and APAC started to perform a bit more better during the Q4 compared to the Q3. On the profit side, quite a lot of down. I think it's good to understand a couple of things regarding to the EBIT development and comparing to the last year. So we had a couple of bigger buckets here, which had an impact to the EBIT performance for the Q4. So the first one was related to the delayed price increases that cost on the bottom line about half a million euros, 2% on the GM level. Then we had roughly half a million non-recurring costs and then bit more increased costs on the FDA side. And then if you go back to the ...